This suggests that the presence of detectable mutant BRAF in serum of patients with BRAF+ tumours is not associated with a poorer prognosis on the basis of PFS compared with patients with BRAF+ tumours in whom BRAF mutations are not detected in cfDNA . This evidence concerns the gene BRAF and neoplasm.